Samumed Company
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Technology:
Regenerative Medicine
Industry:
Biotechnology, Health Care, Life Science
Headquarters:
San Diego, California, United States
Founded Date:
2008-01-01
Employees Number:
51-100
Investors Number:
5
Total Funding:
$658M
Estimated Revenue:
$10M to $50M
Last Funding Type:
Series C
Register and Claim Ownership